DFNB59 Gene Mutations and its Association with Deafness in Schoolchildren in Kohgilooyeh & Boyerahmad Province

Introduction & Objective: Hearing loss is a common disease affecting millions of people worldwide. Hearing loss can be caused due to genetic or environmental factors or even both. The genetic of hearing defect is highly heterogeneous and more than 100 genes are predicted to cause this disorder in humans. A newly identified gene (DFNB59) has been shown to cause deafness in some populations. Here we report mutation analysis for DFNB59 gene in 88 genetic non-syndromic hearing loss subjects. Materials & Methods: In this descriptive-lab based study which was conducted at the Cellular and Molecular Research Center of Shahrekord University of Medical Sciences, DNA was extracted from the peripheral blood samples using standard phenol chloroform procedure. Mutation analysis for DFNB59 gene was performed using PCR-SSCP/HA protocol. The suspected DFNB59 which was detected as shifted bands on PAGE were then confirmed by direct sequencing strategy. Results: Two DFNB59 polymorphisms including c.793C>G and c.793C>T were detected in 8 and 1 deaf subjects respectively. Conclusion: We conclude that there is no association between DFNB59 mutations and deafness in the studied patients in the region

Study of three common mitochondrial mutations in Arab patients with nonsyndromic hearing loss in Khuzestan province, I.R.Iran

زمینه و هدف : ناشنوایی یکی از شایع ترین اختلالات حسی –عصبی است که در هر 1000 تولد زنده رخ می دهد. بیشتر ناشنوایی ها منشا ژنتیکی داشته و حدود 2-0 موارد ناشنوایی مربوط به جهش در ژن های میتوکندریایی است. این مطالعه با هدف بررسی فراوانی سه جهش میتوکندریایی A1555G ، A3243G و A7445G در ناشنوایان غیر سندرمیک استان خوزستان انجام شده است. روش بررسی: در این مطالعه توصیفی 62 دانش آموز ناشنوای غیر سندرومیک با الگوی اتوزومی مغلوب عرب استان خوزستان به روش آسان انتخاب شدند. DNA با روش استاندارد فنل کلروفرم استخراج و جهش های احتمالی در سه ژن میتوکندریایی شامل A1555G ، G3243A و A7445G با روش چند شکلی طول قطعه محدود ( PCR-RFLP ) غربالگری شد. در نهایت جهش های احتمالی به روش توالی یابی مستقیم مورد بررسی و تائید قرار گرفتند. یافته ها: در این مطالعه هیچ یک از جهش های A1555G ، A3243G و A7445G یافت نشد، با این حال دو جهش G3316A و A7445C در دو بیمار مورد مطالعه یافت شد. نتیجه گیری: این مطالعه نشان می دهد که جهش های میتوکندریایی G3316A و A7445C مسئول تعداد کمی از ناشنوایی های قبل از زبان باز کردن در جمعیت استان خوزستان می باشند و جهش های A1555G ، A3243G و A7445G در ایجاد ناشنوایی در این جمعیت نقشی نداشته اند. مطالعه ی حاضر خواهد توانست مشاوران ژنتیک در استان خوزستان را در برنامه مشاوره ژنتیک ناشنوایی خانواده ی بیماران ناشنوا یاری کند

DFNB59 Gene Mutation Screening Using PCR-SSCP/HA Technique in Non-syndromic Genetic Hearing Loss in Bushehr Province

Background: Hearing impairment (HI) is the most prevalent Neurosensory disorder which is heterogenous and can also occur due to environmental causes. The majority of hearing deficiencies are of genetic origin affecting about 60% of the HI cases. A novel gene DFNB59 encodes pejvakin has been recently shown to cause deafness. This study aims to determine the frequency of DFNB59 gene mutations in coding region the gene in Bushehr province. Methods: In this descriptive experimental study, we investigated the presence of DFNB59

DFNB59 gene mutations screening in non syndromic deaf subjects in Chaharmahal va Bakhtiari province

زمینه و هدف: وقوع ناشنوایی پیش زبانی حدود 1 در 1000 تولد است که بیش از 60 موارد آن ارثی هستند. ناشنوایی اختلالی هتروژن محسوب می شود و ممکن است به علل محیطی، ژنتیکی یا هر دو رخ دهد. اخیراً جهش های ژن DFNB59 که رمز کننده پروتئین پژواکین است به عنوان عامل ناشنوایی نوع عصبی معرفی شده اند. این مطالعه با هدف بررسی نوع و فراوانی جهش های ژن DFNB59 در 100 ناشنوای غیرسندرومی، در استان چهارمحال و بختیاری انجام شد. روش بررسی: در این مطالعه توصیفی- آزمایشگاهی، فراوانی جهش های ژنDFNB59 در کل اگزون های کد کننده این ژن بررسی گردید. DNA از نمونه های خون محیطی به روش استاندارد فنل کلروفرم استخراج شد. وجود جهش های DFNB59 با روش غربالگری /Heteroduplex Analysis (HA) PCR- SSCP بررسی گردید. سپس جهش های مشاهده شده در اگزون های 2 و 4 با استفاده از روش PCR- RFlP اگزون شماره 6 با استفاده ار تکنیک Nested PCR و اگزون شماره 7 به کمک تعیین توالی تایید گردید. یافته ها: در این تحقیق 3 نوع پلی مورفیسم ژنی (793C>T 793C>G و 874G>A) و یک نوع جهش 988delG به ترتیب با فراوانی 7، 5، 2 و 1 شناسایی شد. نتیجه گیری: مطالعه حاضر و تحقیقات قبلی حاکی از نقش اندک جهش های ژن پژواکین در ایجاد ناشنوایی در استان چهارمحال و بختیاری است و نتیجه اینکه از نظر بالینی جهش های ژن DFNB59 اهمیت چندانی در این منطقه ندارند

Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions

Background and Objective: This review comprehensively explores the intricate landscape of anaplastic lymphoma kinase (ALK), focusing specifically on its pivotal role in non-small cell lung cancer (NSCLC). Tracing ALK’s discovery, from its fusion with nucleolar phosphoprotein (NPM)-1 in anaplastic large cell non-Hodgkin’s lymphoma (ALCL) in 1994, the review elucidates the subsequent impact of ALK gene alterations in various malignancies, including inflammatory myofibroblastoma and NSCLC. Approximately 3–5% of NSCLC patients exhibit complex ALK rearrangements, leading to the approval of six ALK-tyrosine kinase inhibitors (TKIs) by 2022, revolutionizing the treatment landscape for advanced metastatic ALK + NSCLC. Notably, second-generation TKIs such as alectinib, ceritinib, and brigatinib have emerged to address resistance issues initially associated with the pioneer ALK-TKI, crizotinib. Methods: To ensure comprehensiveness, we extensively reviewed clinical trials on ALK inhibitors for NSCLC by 2023. Additionally, we systematically searched PubMed, prioritizing studies where the terms “ALK” AND “non-small cell lung cancer” AND/OR “NSCLC” featured prominently in the titles. This approach aimed to encompass a spectrum of relevant research studies, ensuring our review incorporates the latest and most pertinent information on innovative and alternative therapeutics for ALK + NSCLC. Key Content and Findings: Beyond exploring the intricate details of ALK structure and signaling, the review explores the convergence of ALK-targeted therapy and immunotherapy, investigating the potential of immune checkpoint inhibitors in ALK-altered NSCLC tumors. Despite encouraging preclinical data, challenges observed in trials assessing combinations such as nivolumab-crizotinib, mainly due to severe hepatic toxicity, emphasize the necessity for cautious exploration of these novel approaches. Additionally, the review explores innovative directions such as ALK molecular diagnostics, ALK vaccines, and biosensors, shedding light on their promising potential within ALK-driven cancers. Conclusions: This comprehensive analysis covers molecular mechanisms, therapeutic strategies, and immune interactions associated with ALK-rearranged NSCLC. As a pivotal resource, the review guides future research and therapeutic interventions in ALK-targeted therapy for NSCLC

Curcumin supplementation contributes to relieving anthropometric and glycemic indices, as an adjunct therapy: A meta-research review of meta-analyses

Background: Curcumin, a natural polyphenolic compound, can affect anthropometric and glycemic indices; however, the findings of existing meta-analyses are controversial. Study design: The current umbrella meta-analysis was performed among present systematic reviews and meta-analyses to investigate the effect of curcumin supplementation on anthropometric and glycemic indices. Methods: A comprehensive systematic search was performed on Embase, PubMed, WOS, Scopus, and Cochrane Library to obtain peer-reviewed papers published before 30/November/2021. meta-analysis was conducted using the random-effects model. Results: 12 meta-analyses were included in the current study. Our results have revealed that the curcumin supplementation can significantly decrease body mass index (BMI) (ES: −0.26; 95 % CI: −0.38, −0.14, p < 0.001; I2 = 0.0 %, P = 0.842), body weight (BW) (ES: −0.55; 95 % CI: −0.99, −0.12, p = 0.013; I2 = 81.1 %, p < 0.001), waist circumference (WC) (ES: −0.66; 95 % CI: −1.23, −0.09, p = 0.023; I2 = 72.4 %, p = 0.003), fasting blood sugar (FBS) (ES: −1.63; 95 % CI: −2.36, −0.89, p < 0.001; I2 = 88.4 %, p < 0.001), homeostasis model assessment-estimated insulin resistance (HOMA-IR) (ES: −0.38; 95 % CI: −0.48, −0.28, p < 0.001;I2 = 35.9 %, p = 0.142), hemoglobin A1c (HbA1c) (ES: −0.44; 95 % CI: −0.67, −0.21, p < 0.001;I2 = 65.0 %, p = 0.014), and insulin (ES: −0.86; 95 % CI: −1.52, −0.21, p = 0.010; I2 = 92.5 %, p < 0.001). Conclusion: These findings recommend curcumin supplementation as a favorable intervention to improve anthropometric and glycemic indices